Company Encyclopedia
View More
name
I-Mab
IMAB.US
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc.
1.946 T
IMAB.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Short Interest in I-Mab Sponsored ADR (NASDAQ:IMAB) Increases By 38.8%

    I-Mab Sponsored ADR (NASDAQ:IMAB) experienced a significant increase in short interest, rising 38.8% to 3,650,000 shares as of October 15th. This represents 5.7% of the company's stock being short sold, with a days-to-cover ratio of 1.4 days based on an average daily trading volume of 2,660,000 shares. The stock traded up 2.5% to $4.76, with a market cap of $388.29 million. Analysts maintain a "Moderate Buy" rating with a consensus target price of $7.67, reflecting positive sentiment towards the company's future performance.

    Market Beat·
    US
    IMAB
    0.00%
    Market Beat·
    US
    IMAB
    0.00%

    I-Mab's (IMAB) Sell (D-) Rating Reaffirmed at Weiss Ratings

    Weiss Ratings has reaffirmed a "sell (d-)" rating on I-Mab (NASDAQ:IMAB) shares. Other brokerages have set various target prices, with Loop Capital at $8.00 and Leerink Partners at $9.00. I-Mab's stock rose 2.5% to $4.76, with a market cap of $388.29 million. The company reported earnings of ($0.07) per share, exceeding estimates. Institutional investors hold 38.38% of the stock. I-Mab is a clinical-stage biopharmaceutical company focused on immuno-oncology and immuno-inflammation diseases, currently developing several treatments in clinical trials.

    Market Beat·
    US
    IMAB
    0.00%
    Market Beat·
    US
    IMAB
    0.00%

    I-Mab Files for Dual Primary Listing on Hong Kong Stock Exchange

    I-Mab NovaBridge Biosciences has filed for a dual primary listing of its ordinary shares on the Hong Kong Stock Exchange, with an accompanying initial public offering. The shares have a par value of US$0.0001 each. This announcement is for informational purposes and should not be considered financial or legal advice.

    Reuters·
    US
    NBP
    +3.64%
    US
    IMAB
    0.00%
    Reuters·
    US
    NBP
    +3.64%
    US
    IMAB
    0.00%

    I-Mab Subsidiary Visara Assigns VIS-101 License to Everest Medicines

    I-Mab's subsidiary Visara has assigned its exclusive license for VIS-101 to Everest Medicines. This agreement allows Everest Medicines to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and select Southeast Asian countries. The information was originally published by I-Mab via EDGAR on October 30, 2025.

    Reuters·
    US
    IMAB
    0.00%
    HK
    01952
    +0.22%
    US
    NBP
    +3.64%
    Reuters·
    US
    IMAB
    0.00%
    HK
    01952
    +0.22%
    US
    NBP
    +3.64%

    NovaBridge Biosciences Unveils New Identity and Strategic Direction

    I-MAB has rebranded as NovaBridge Biosciences, with shareholders approving the name change on October 24, 2025. The new ticker symbol 'NBP' will be used starting October 30, 2025. This strategic shift aims to enhance capital access and innovation through a dual listing on Nasdaq and the Hong Kong Stock Exchange. The company has launched a subsidiary, Visara, Inc., for ophthalmic therapeutics and is advancing clinical trials for its core assets. Analyst ratings reflect a cautious outlook due to financial challenges, with a recent Buy rating and a $7.00 price target for the stock.

    Tip Ranks·
    US
    IMAB
    0.00%
    US
    NBP
    +3.64%
    Tip Ranks·
    US
    IMAB
    0.00%
    US
    NBP
    +3.64%
    © 2025 Longbridge｜Disclaimer